XFOR (X4 Pharmaceuticals) Short Percentage of Float


XFOR X4 Pharmaceuticals Inc XFOR
29 GF Score
Price $4.12
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XFOR vs ZURA, LYEL, LXEO: Short Percentage of Float Comparison

For the Biotechnology subindustry, X4 Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Short Percentage of Float falls into.


XFOR
29GF Score
X4 Pharmaceuticals Inc XFOR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for XFOR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.12
Price